Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 3

Episode 3:
Panel Discussion & Pearls for Practice
Aristotelis Bamias, MD, PhD, Philippe Barthélémy, MD, PhD and Kate Smith, MBBS, MRCP, MD, PhD

The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different clinical scenarios following progression of 1L therapies. In this educational program on 'Best Practice Exchange in Clinical Case Scenarios', field experts will discuss the latest evidence supporting the optimal utilization of sequential treatments, including immunotherapy, chemotherapy (CT), antibody-drug conjugates (ADCs), and targeted therapies, to prolong continuum of care and maximize survival benefits for patients. A better understanding of how to sequence available options for second-line (2L) and salvage treatments in routine patient care will facilitate optimal management of urothelial cancer patients.